Phibro Animal Health Q2 revenue beats estimates on vaccine demand

Overview

• Animal health firm's Q2 revenue rose 21%, beating analyst expectations

• Adjusted EBITDA for Q2 rose 41%, beating analyst expectations

• Company raised fiscal 2026 guidance for net sales and adjusted EBITDA

Outlook

• Phibro raises fiscal 2026 net sales guidance to $1.45 bln-$1.50 bln

• Company expects fiscal 2026 adjusted EBITDA of $245 mln-$255 mln

• Phibro forecasts fiscal 2026 adjusted net income of $120 mln-$127 mln

Result Drivers

• MFA PORTFOLIO - Faster than expected uptake of newly integrated MFA portfolio boosted results

• NUTRITIONAL SPECIALTY GROWTH - Strong demand for nutritional specialty products, particularly in North America, contributed to sales growth

• VACCINE DEMAND - Growth in vaccine sales driven by increased demand in Latin America and Southeast Asia

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Phibro Animal Health Corp is $45.00, about 8.9% above its February 3 closing price of $41.31

• The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nBw2W1bc5a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.